Financials
Financial year 2025
Worth noting
- Little cash and receivables against the short-term debts.
Gross margin
€ 257,722
▲ 134% vs 2024
Profit
Growing€ 51,670
▲ 128% vs 2024
Debts
Normal€ 5.9 million
▲ 3% vs 2024
CREDOPHAR from Gent, company number BE0849730193, closed financial year 2025 with a result of € 51,670 after tax. For that financial year CREDOPHAR recorded a gross margin of € 257,722 and equity of € 1.9 million. Compared with financial year 2024, the result moved from € -182,309 to € 51,670. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.
What happened at CREDOPHAR?
What happened at CREDOPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 51,670. filed late Source: NBB ↗
- Aquitania BV stepped down as director. NBB
- MD Consult BV stepped down as director. NBB
- Aquitania BV became a director. NBB
- MD Consult BV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 686,939 profit in 2021 to € 51,670 profit in 2025.
Paid € 528,951 in corporate taxes since 2021.
Best year ever: 2021, with € 686,939 profit.
On average € 236,500 of value added per employee in 2022.
A new publication or filing at CREDOPHAR? We notify you, reason included.
Follow CREDOPHARNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by Anja Imschoot
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium +6 more
since 2021 · until 2026
Director · represented by Mario Debel
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, 2PHARMA HOLDING +5 more
since 2021 · until 2026
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
+15 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Website info
Features
Security
Details
- Company number
- 0849.730.193
- VAT number
- BE 0849.730.193
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- CREDOPHAR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 October 2012
- Peppol
- Active · Active since 17 Jul 2025
- Contact
- credophar.be info@credophar.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in andere specifieke goederen